Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Director comp.
CC transcript

EXELIXIS, INC. (EXEL) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/02/2018 BW Exelixis Announces First Quarter 2018 Financial Results and Provides Corporate Update
04/11/2018 BW Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018
02/26/2018 BW Exelixis Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
01/16/2018 BW Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma
11/21/2017 BW Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations
11/01/2017 BW Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update
10/18/2017 BW Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017
09/09/2017 BW Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017
09/06/2017 BW Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress
08/02/2017 BW Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update
07/17/2017 BW Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017
05/01/2017 BW Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update
04/24/2017 BW Exelixis to Present at the Deutsche Bank 42nd Annual Health Care Conference on May 3
04/18/2017 BW Exelixis to Release First Quarter 2017 Financial Results on Monday, May 1, 2017
02/27/2017 BW Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
02/02/2017 BW Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017
07/21/2011 BW Exelixis Announces August 4th Webcast of Second Quarter 2011 Financial Results Conference Call
07/06/2011 BW Exelixis Provides Update on Cabozantinib Development Activities
06/06/2011 BW Exelixis' Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Metastatic Castration-Resistant Prostate Cancer
06/05/2011 BW Exelixis' Cabozantinib Demonstrates Broad Clinical Activity in Multiple Tumor Types
06/04/2011 BW Exelixis' Cabozantinib Demonstrates Encouraging Clinical Activity in Patients with Metastatic Ovarian Cancer
06/01/2011 BW Exelixis Announces Webcasts of June Investor Conference Presentations
05/31/2011 BW Reminder: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting
05/23/2011 BW Data From a Phase 1 Clinical Trial of Exelixis' Cabozantinib Published in the Journal of Clinical Oncology
05/18/2011 BW Exelixis Launches Online Summit Featuring Expert Perspectives on Cancer Treatment Advances and ASCO Highlights
05/13/2011 BW UPDATED: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting
05/13/2011 BW UPDATED: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting
05/09/2011 BW CORRECTING and REPLACING Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/03/2011 BW Exelixis Announces First Quarter 2011 Financial Results
04/27/2011 BW Exelixis Announces May 4th Webcast of Presentation at the Deutsche Bank Securities Health Care Conference
04/21/2011 BW Exelixis Announces May 3rd Webcast of Its First Quarter 2011 Financial Results Conference Call
04/04/2011 BW Exelixis Announces April 7th Webcast of Presentation at the Leerink Swann Cancer Roundtable Conference
03/15/2011 BW Exelixis Announces Exercise in Full of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
03/09/2011 BW Exelixis Announces Pricing of $165.0 Million Public Offering of Common Stock
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy